• Tolerability (maximum tolerated dose) [ Designated as safety issue: Yes ]
• Time to treatment related toxicity as assessed by hematologic measures and CTC criteria [ Designated as safety issue: Yes ]
• Time to treatment related ≥ grade 3 toxicity [ Designated as safety issue: Yes ]
• Time to progression [ Designated as safety issue: No ]
• Time to treatment failure [ Designated as safety issue: No ]
• Early response as assessed by automated morphological MRI change detector and physiological MRI techniques, including diffusion-weighted imaging, perfusion-weighted imaging, and chemical shift imaging [ Designated as safety issue: No ]

• Tolerability (maximum tolerated dose)
• Time to treatment related toxicity as assessed by hematologic measures and CTC criteria
• Time to treatment related ≥ grade 3 toxicity
• Time to progression
• Time to treatment failure
• Early response as assessed by automated morphological MRI change detector and physiological MRI techniques, including diffusion-weighted imaging, perfusion-weighted imaging, and chemical shift imaging

• Inhibition status of mTOR signaling pathways in peripheral blood mononuclear cells [ Designated as safety issue: No ]
• Potential pharmacokinetic interactions [ Designated as safety issue: No ]
• Correlate survival, progression-free survival, and response with pre-treatment tumor tissue molecular markers [ Designated as safety issue: No ]

• Inhibition status of mTOR signaling pathways in peripheral blood mononuclear cells
• Potential pharmacokinetic interactions
• Correlate survival, progression-free survival, and response with pre-treatment tumor tissue molecular markers

RATIONALE: Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving temsirolimus together with temozolomide and radiation therapy may kill more tumor cells.

PURPOSE: This phase I trial is studying the side effects and best dose of temsirolimus when given together with temozolomide and radiation therapy in treating patients with newly diagnosed glioblastoma multiforme.

OBJECTIVES:

Primary

• Determine the maximum tolerated dose of temsirolimus when administered with temozolomide in combination with radiotherapy followed by adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme.
• Assess and describe the adverse events associated with this regimen in these patients.
• Evaluate the early response to therapy in these patients using an automated morphological MRI change detector and physiological MRI techniques, including diffusion-weighted imaging, perfusion-weighted imaging, and chemical shift imaging.

Secondary

• Determine the inhibition status of mTOR signaling pathways in peripheral blood mononuclear cells in patients treated with this regimen.
• Identify potential pharmacokinetic interactions between temozolomide and temsirolimus.
• Correlate, preliminarily, survival, progression-free survival, and response with pre-treatment tumor tissue molecular markers in these patients.

OUTLINE: This is a multicenter, dose-escalation study of temsirolimus. Patients are assigned to 1 of 2 treatment groups.

• Group 1 (temsirolimus with radiation and temozolomide): Patients receive temsirolimus IV over 30 minutes once weekly. Beginning 7-10 days later, patients also receive oral temozolomide daily and undergo concurrent 3-D conformal radiotherapy or intensity-modulated radiotherapy once daily, 5 days a week, for 6 weeks. Patients are evaluated 4-6 weeks after completion of chemoradiotherapy. Patients with stable or responding disease proceed to adjuvant therapy.

Cohorts of 3-6 patients receive escalating doses of temsirolimus until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience a dose-limiting toxicity. At least 6 patients are treated at the MTD.

• Group 2 (radiation and temozolomide): Patients receive oral temozolomide daily and undergo concurrent 3-D conformal radiotherapy or intensity-modulated radiotherapy once daily, 5 days a week, for 6 weeks. Patients are evaluated 4-6 weeks after completion of chemoradiotherapy. Patients with stable or responding disease proceed to adjuvant therapy.
• Adjuvant therapy: Beginning 4-6 weeks after the completion of chemoradiotherapy patients receive oral temozolomide on days 1-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

Some patients undergo blood collection for immune monitoring and translational/pharmacologic studies.

After completion of study treatment, patients are followed periodically for 5 years.

PROJECTED ACCRUAL: A total of 46 patients will be accrued for this study.

• Drug: temozolomide
• Drug: temsirolimus
• Other: pharmacological study
• Procedure: adjuvant therapy
• Radiation: 3-dimensional conformal radiation therapy
• Radiation: intensity-modulated radiation therapy

DISEASE CHARACTERISTICS:

• Histologically confirmed glioblastoma multiforme (GBM)

  • Gliosarcoma and other grade 4 astrocytoma variants (e.g., giant cell glioblastoma) allowed

• Newly diagnosed disease

  • Has undergone surgical resection or biopsy of the tumor at least 1 week but no more than 6 weeks ago

PATIENT CHARACTERISTICS:

• ECOG performance status 0-2
• Absolute neutrophil count ≥ 1,500/mm^3
• Hemoglobin ≥ 9.0 g/dL
• Platelet count ≥ 100,000/mm^3
• Total bilirubin ≤ 2.5 times upper limit of normal (ULN)
• Cholesterol < 350 mg/dL
• Triglycerides < 400 mg/dL
• AST ≤ 2.5 times ULN
• Creatinine ≤ 1.5 times ULN
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No history of allergy or intolerance to dacarbazine
• No ongoing or active infection
• No symptomatic congestive heart failure
• No unstable angina pectoris
• No cardiac arrhythmia
• No psychiatric illness or social situation that would preclude study compliance
• No other uncontrolled illness
• No gastrointestinal tract disease affecting ability to take oral medication or requiring IV alimentation
• No significant traumatic injury within the past 21 days
• No active, uncontrolled peptic ulcer disease
• No other active cancers requiring therapy

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics
• Willing and able to comply with antibiotic prophylaxis with either trimethoprim/sulfamethoxazole (daily or 3 times per week) or monthly IV pentamidine combined with daily levofloxacin
• No prior chemotherapy for any brain tumor
• No prior temozolomide or mTOR inhibitor therapies
• No prior cranial radiotherapy
• More than 21 days since prior major surgery (excluding neurosurgical biopsy or resection of GBM)
• No prior surgical procedures affecting absorption

• No concurrent enzyme-inducing anticonvulsants, including any of the following:

  • Carbamazepine
  • Phenytoin
  • Phenobarbital
  • Primidone
• No other concurrent investigational agents

• Not receiving warfarin prior to study registration

  • Concurrent warfarin allowed if patients develop an indication for it while enrolled on the protocol
• No concurrent combination antiretroviral therapy for HIV-positive patients